U.S. Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number

Under the Paperwork Reduction Act of 1995, no person are required to respond to respond

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

SHEET 1 of 4

COMPL	ETE IF KNOWN
Application Number	10/662,644
Confirmation Number	9385
Filing Date	September 15, 2003
First Named Inventor	Haught et al.
Group Art Unit	1616
Examiner Name	Not Yet Assigned
Attorney Docket Number	8170XR

U. S. PATENT DOCUMENTS

NITIALS'	No.1	DOCUMENT NUMBER	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines Where Relevant Passages or Relevan
<u> </u>		Number - Kind Code ² (If known)	MM-DD-YYYY	Cited Document Stecker et al.	Figures Appear
DVI	1	US-2,906,711	09/29/1959	Schenkel et al.	
	2	US-3,968,210	070/6/1976		
<u> </u>	3	US-3,989,827	11/02/1976	Apostolatos et al. Rubinfeld et al.	
	4	US-4,061,603	12/06/1977	Stecker et al.	
	5	US-3,041,236	06/26/1962		
	6	US-3,666,668	05/30/1972	Klausner et al.	
	7	US-5,919,152	07/06/1999	Zygmont et al.	ļ
	8	US-6,017,871	07/25/2000	Baeck et al.	
	9	US-4,287,191	09/01/1981	Coburn et al.	
	10	US-4,358,443	11/09/1982	Coburn et al.	
	11	US-5,958,911	09/28/1999	Evans et al.	
	12	US-6,117,859	9/12/2000	Evans et al.	
	13	US-4,560,549	12/24/1985	Ritchey et al.	ļ
	14	US-4,647,452	030/3/1987	Ritchey et al.	· · · · · · · · · · · · · · · · · · ·
	15	US-4,742,083	05/3/1988	Ritchey et al.	
	16_	US-4,725,590	02/16/1988	Ritchey et al.	
	17	US-4,939,132 equivalent to EP 0 198 366	07/03/1990	Coburn et al.	
	18	US-4,560,549 equivalent to EP 0 221 211	12/24/1985	Ritchey	
	19	US-4,287,191 equivalent to EP 0 038 191	09/01/1981	Coburn et al.	
	20	US-4,358,443 equivalent to EP 0 038 192	110/9/1982	Coburn et al.	
1	21	US-3,311,562 equivalent to GB 1,088,498	03/28/1967	Stecker	·
	22	US-3,666,808 equivalent to GB 1,254,999	05/30/1972	Meek	
	23	US-3,312,524	-05/23/1967	Harich	
+	24	US-2002/0068014 A1	06/06/2002	Haught et al.	
	25	US-2,092,300 A	09/07/1937	Bogin	
+	26	US-3,256,200 A	06/14/1966	William	† · · · · · · · · · · · · · · · · · · ·
			07/20/1971	Wilson	
	27 28	US-3,594,322 A US-3,664,961	05/23/1072	Norris	
	29	US-3,666,668	05/30/1972	Klausner	
			02/15/1977	Sawatari Kenichi etal.	
	30	US-4,008,274 A	08/30/1994	Gavin	
 -	31	US-5,342,437 A	11/19/1996	Miracle et al.	
	32	US-5,576,282	02/25/1997	Damhus et al.	
+	33	US-5,605,832	07/08/1997	MacBeath	
+		US-5,646,101	11/04/1997	Dallmier et al.	
 	35	US-5,683,654	11/11/1997	Baillely et al.	
+	36	US-5,686,014		Christie et al	+
	37	US-5,695,679	12/09/1997	Christie et al.	
	38	US-5,698,504	12/16/1997		
	39	US-5,705,464	01/06/1998	Scheper et al.	
<u> </u>	40	US-5,707,950	01/13/1998	Kasturi etal.	
m	41	US-5,710,115 US-5,728,671	01/20/1998	Patel et al. Rohrbaugh et al.	

 43	US-6,159,720 equivalent of	12/12/2000	Murashima et al.	
	WO 98/03640 A			<u></u>

FOREIGN PATENT DOCUMENTS

	_	FOREIGN PATENT DOCU	MENT	T	T	Pages, Columns, Lines Where Relevant Passages	
EXAMINER INITIALS*	Citte No.1		Ind Code ⁸ (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	or Relevant Flaures Appear	T ⁰
mil	44	WO 02/28819 A1		04/11/2002	The Research Foundation of State Univ. of New York		
	45	WO 01/60157 A2		08/23/2001	Procter & Gamble		
1.	46	WO 98/24800 A2		06/11/1998	Magainin Pharmaceuticals		
-+	47	WO 98/39403 A1		09/11/1998	Procter & Gamble		
	48	WO 98/06808 A1		02/19/1998	Procter & Gamble		
	49	WO 98/06805 A1		02/19/1998	Procter & Gamble		
_	50	WO 98/06807 A1		02/19/1998	Procter & Gamble		
	51	WO 98/39404 A1		09/11/1998	Procter & Gamble		
$\overline{}$	52	WO 98/39402 A1		09/11/1998	Procter & Gamble		
	53	WO 98/16604 A2		04/23/1998	Procter & Gamble		<u> </u>
	54	WO 98/40473 A1		09/17/1998	Procter& Gamble		<u> </u>
	55	WO 96/16153 A1		05/30/1996	Procter & Gamble		↓
	56	WO 96/12004 A1		04/25/1996`	Procter & Gamble		
	57	WO 96/16154 A1		05/30/1996	Procter & Gamble		
	58	WO 96/27649 A1		09/12/1996	Procter & Gamble	<u> </u>	├ ─
	59	WO 98/15633 A1		04/16/1998	Emalfarb	<u> </u>	
	60	WO 98/06809 A1		02/19/1998	Procter & Gamble		——
	61	WO 98/13457 A1		04/02/1998	Procter & Gamble	ļ	├
	62	WO 96/28558 A1		09/19/1996	Procter & Gamble		
	63	WO 98/28394 A1		07/02/1998	Procter & Gamble		
	64	WO 97/09431 A1		03/13/1997	Novo Nordisk Biotech Inc et al.		
	65	WO 97/31090 A1		08/28/1997	Procter & Gamble		
	66	WO 97/11164 A1		03/27/1997	Genencor Int I. Inc.		
	67	WO 99/09126 A1		02/25/1999	Procter & Gamble		<u> </u>
- -	68	WO 98/50513 A1		11/12/1998	Procter & Gamble		
	69	WO 99/02663 A1		01/21/1999	Novo Nordisk A/S		<u> </u>
	70	WO 98/38287 A1		09/03/1998	Novo Nordisk A/S		
	71	WO 98/38286 A1		09/03/1998	Novo Nordisk A/S		<u> </u>
	72	WO 98/27197 A1		06/25/1998	Novo Nordisk A/S		——
	73	WO 98/10060 A1		03/12/1998	Novo Nordisk A/S	<u> </u>	—
	74	WO 98/27198 A1		06/25/1998	Novo Nordisk A/S		╄
	75	WO 97/11217 A1		03/27/1997	Novo Nordisk A/S		┿
	76	WO 97/25468 A1		07/17/1997	Novo Nordisk A/S		—
	77	WO 97/25469 A1		07/17/1997	Novo Nordisk A/S		┼
	78	WO 97/40127 A1		10/30/1997	Novo Nordisk A/S		
	79	WO 97/40229 A1		10/30/1997	Novo Nordisk A/S		
	80	WO 97/08325 A1		03/06/1997	Novo Nordisk Biotech Inc. et al.		
	81	WO 97/28257 A1		08/07/1997	Novo Nordisk A/S		+
	82	WO 98/07816 A1		02/26/1998	Procter & Gamble	 	4
	83	WO 95/26397 A1		10/05/1995	Novo Nordisk A/S		+-
	84	WO 96/23873 A1		08/08/1996	Novo Nordisk A/S		+
	85	WO 95/35382 A2		12/28/1995	Gistbrocades B.V.		+
	86	EP 0 747469 A1		12/11/1996	Procter & Gamble	 	+
	87	EP 0 709 452 A1		05/01/1996	Procter & Gamble		┼
	88	E 0 747 470 A1		12/11/1996	Procter & Gamble		+
	89	EP 0 698 659 A1		02/28/1996	Procter & Gamble		+
	90	GB 848,306		09/14/1960	Colgate-Palmolive		+
	91	GB 2 297 979 A		08/21/1996	Procter & Gamble		+
	92	GB 2 294 269 A		04/24/1996	Procter & Gamble		+
	93	GB 2 303 147 A		02/12/1997	Procter & Gamble		╫
	94	JP 57-142,903		09/03/1982	Dainippon Ink & Chemical	ļ	 ×
	95	JP 10088485 A		04/07/1998	Funayama et al.		X
	96	JP 10174583 A		06/30/1998	Echigo et al.		X
	97	JP 09316490 A		12/09/1997	Suzuki et al.		X
\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	98	JP 10088472 A		04/07/1998	Matsuyama et al.	 	 x
OWY	99	CH 500 661		02/15/1971	Ciba-Geigy		┸^

And	100	BE 528,076 equivalent of FR 528,076	01/18/1957	Ciba Societe Anonyme	×
Ø: 1	101	FR 1,071,945	09/07/1954	CIBA	X
	102	DE 2,157,209	05/24/1973	Henkel & Cie GmbH	X
	103	DE 4428380 A1	2/15/1996	Bayer	X
	104	DE 195 23389 A1	01/09/1997	Bayer AG	X
	105	DE 196 12193 A1	10/02/1997	Consortium for the Electrochemical Industry GmbH	Х
	106	CH 449,571 equivalent of 2071/65	09/15/1967	Stecker International	X
OM	107	FR 500,661		CIBA Geigy	
EXAMINE	1	The Vyor		DATE CONSIDERED 9/1/05	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

EXAMINEH: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Preservet Paduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO	COMPLETE IF KNOWN		
	Application Number	10/662,644	
INFORMATION DISCLOSURE	Confirmation Number	9385	
STATEMENT BY APPLICANT	Filing Date	September 15, 2003	
(use as many sheets as necessary)	First Named Inventor	Haught et al.	
•	Group Art Unit	1616	
•	Examiner Name	TBD	
SHEET 4 of 4	Attorney Docket Number	8170XR	

NON PATENT LITERATURE DOCUMENTS

EXAMINER	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial,	τ°		
INITIALS*	No.'	symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published			
YUXA	108	NATARAJAN ET AL., 1992, Indian Drugs 29:545-552			
	109	LEMAIR ET AL., 1961 J. Pharmaceutical Sciences, 50:831-837			
	110	CIAMPA G. ET AL. "N-Substituted salicylanilides. I. Halogenated 2-hydroxy- and 2-acetoxybenanilides with antibacterial and antifungal activity" Vol. 68, No. 21, 6001 Chemical Abstracts, Columbus, OH, USA XP002177845 ISSN: 0009-2258 abstract,			
	111	Abstract XP 002177846 equivalent to abstract for cite 117			
	112	SMITH FT AL. Fungitoxic derivatives of salicyladehyde, 1961, Ann. Appl. Biol. Vol. 49, ppl 102-9			
	113	GUREVICH, E. S. ET AL. "Use of org. poisons in antifouling paints" retrieved from STN Database accession no 5293a XP002191164 & Chemical Abstracts, vol. 64, no. 4, February 14, 1966			
	114	HOFFMAN, ERICH ET AL. "Formulation of fungus-resistant paints. V. Addition of salicianilide" retrieved from STN Database accession no. 71:51292 XP002191175 abstract & J. Oil Colour Chem. Ass. (1969), 52(7)			
	115	Medicinal Chemistry, Vol. 28, 1985, pages 143-146			
	116	J. H. AMIN, "The Fries Reaction, part IV-The Rearrangement of the Derivatives of Salicylic Acid & Substituted Benzoic Acids, Scientific & Industrial Research, Vol. 138, No. 1, 1954, pages 178-179			
Onl	117	to the second design of the second se	X		
EXAMINE	R V	DATE CONSIDERED 9/1/05			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional).
Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 37 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO-SB08 (Revised for P&G use 10/8/2003)